Evaluation of the sensitization potential of baby care formulation on healthy human subjects - NI

FemiCura HealthTech Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•1. Female and male Asian Indian subjects.
•2. Healthy Human subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup)
•3. Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….)

•1. For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
•2. Having refused to give his or her assent by not signing the consent form
•3. Taking part in another study liable to interfere with this study
•4. Being diabetic.
•5. Being asthmatic.
•6. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
•7. Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin).
•8. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
•9. Having undergone a surgery requiring a general anaesthesia of more than one hour in the past 6 months.
•10. Having changed his or her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.
•11. The day of the patch application: no cosmetic product must be used (test site clean with water only).

发起方

FemiCura HealthTech Pvt Ltd